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Plants have been shown to be an excellent source of new drugs, including 
anticancer agents. Rhus coriaria, commonly known as sumac, a plant that is known to 
possess different therapeutic values including anti-oxidant and anti-microbial 
activities. Here, we investigated the anti-cancer effect of R. coriaria on triple negative 
MDA-MB-231 cell line. We demonstrated that Rhus coriaria ethanolic extract (RCE) 
inhibits the proliferation of MDA-MB-231 cell line in a time- and concentration-
dependent manner. RCE induced senescence and cell cycle arrest at G1 phase. 
Moreover, no proliferative recovery was detected after RCE removal. Annexin V 
staining and PARP cleavage analysis revealed a minimal induction of apoptosis in 
MDA-MB-231 cells. Autophagy vacuoles were detected along with autophagy 
markers. Interestingly, blocking autophagy by 3-methyladenine (3-MA) or 
chloroquine (CQ) reduced RCE-induced cell death and senescence. Finally, RCE 
induced DNA damage, an event that was found to precede autophagy. Hence, 
altogether, these findings make Rhus coriaria a promising alternative candidate 
against breast cancer. 
 
Keywords: Rhus coriaria, triple negative breast cancer, apoptosis, senescence, cell 







Title and Abstract (in Arabic) 
 
 أثر نبات السماق المضاد لسرطان الثدي
 صالملخ
 ذهأحد ه تستخدم النباتات في صنع األدوية الجديدة التي تتضمن مضادات السرطان.
 . أشارت الدراسات السابقة على يعرف بنبات السماق و (Rhus coriaria)نبات ال النباتات هو 
سة في هذه األطروحة بدراوبالتالي قمنا كعالج مضاد لألكسدة ومضاد حيوي.  فاعلية نبات السماق
اق يمنع السم نبات إلى أن. ولقد توصلنا في هذا الدراسة سرطان الثديعلى  السماقمستخلص أثر 
أدى كما أنه باالعتماد على الوقت والتركيز.  (MDA-MB-231)وتكاثر الخاليا السرطانية نمو 
في الخاليا (senescence) وإلى الشيخوخة  (cell cycle arrest) إلى إيقاف دورة حياة الخلية
بل  السماق د إزالةلخاليا السرطانية بعاتكاثر فإن نبات السماق منع  باإلضافة إلى ذلك .السرطانية
الخاليا تموت بعملية بعض . لقد وجدنا أن وأدى إلى موتها حتى بعد إزالة السماق من الخاليا
ولكن العملية الرئيسية التي وجدناها لموت الخاليا السرطانية هي  ،(apoptosis) الموت الذاتي
-3بمواد كيميائية خاصة عملية الموت الذاتي وعندما منعنا. (autophagy)الموت الذاتي للخاليا 
MA)   أو(CQ كما وجدنا أن السماق يؤدي إلى إلحاق لخالياقلت نسبة الشيخوخة وموت ا .
كل هذه النتائج تجعل  الخاص بالخاليا السرطانية. (DNA damage) الضرر بالحمض النووي
 . الثدي نبات السماق بديل واعد كمضاد لسرطان
، ،الموت المبرمج للخالياالسماق، الشيخوخة، دورة حياة الخلية: نبات مفاهيم البحث الرئيسية
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Chapter 1: Introduction 
 
1.1 Cancer  
Cancer remains one of the leading causes of morbidity and mortality. It is a 
major public health problem worldwide.  An estimated 14.1 million new cancer cases 
were diagnosed worldwide in 2012.  Sadly, 8.2 million deaths from cancer occurred in 
the same year. Moreover, it is predicted that by 2020 cancer rates could further increase 
by 50% to reach 15 million new cases[1]. In the United Arab Emirates, 1212 new 
cancer cases were reported in 2012. Cancer is the second leading cause of death in the 
Emirate of Abu Dhabi, and accounts for 15% of total deaths as there were around 407 
deaths caused by cancer in 2012[2]. 
1.1.1 Definition and classification 
Cancer is defined as a multifactorial disease that is characterized by 
uncontrolled cellular growth, invasion and spreading of those cells from their primary 
site to other sites in the body to establish new colonies of cancer cells[3]. Cancers are 
classified upon their tissue of origin. The most common of them are carcinomas which 
arise from epithelial cells, while sarcomas are derived from mesoderm cells. Cancers 
of epithelial cells with glandular organization are called adenocarcinomas[3]. Other 
classes of cancers include lymphoma and leukaemia are derived from white blood cells 
and their precursors[4].  
1.1.2 Hallmarks of cancer  
Cancer cells are distinguished from normal cells by acquiring specific 






their own signals, sustaining proliferative signalling and resisting inhibitory signals 
that might otherwise stop their growth. In addition, evading apoptosis and enabling 
unlimited replicative potential, stimulating angiogenesis, by forming blood vessels to 
supply nutrients to tumors, invading local tissues and metastasize to distant sites. 
Furthermore, reprogramming of energy metabolism and evading immune system 
destruction are emerging hallmarks of cancers that need further study[5].  
1.1.3 Causes of cancer  
While the real cause of cancer is still unknown, many factors have been 
associated with cancer. These factors include genetic mutation in tumor suppressor 
genes and oncogenes, life style, chemical agents and viruses[3].  
1.2 Breast cancer  
Breast cancer represent the most commonly diagnosed cancers in women. 
There were 1.7 million new cases diagnosed in 2012 worldwide. This represents about 
12% of all cancer cases and 25% of all cancers in women[6]. In the United Arab 
Emirates the leading cause of death related to cancer for the same year was breast 
cancer as well[2]. Breast cancers are a heterogeneous and diverse group of diseases 
that comes in several clinical and histological implications. The clinical progression 
of breast cancer is difficult to predict and its current treatment is therefore not as 
effective as it should be[7], [8]. Gene expression profiling using microarray analysis 
assists in creating a working model for a breast cancer molecular taxonomy which has 
become widely used. Using hierarchical cluster analysis breast cancers can be 
classified into one of five molecular subtypes: luminal A and luminal B –both are 
estrogen receptor (ER)-positive- , basal-like (ER)-negative,  human epidermal growth 






1.2.1 Triple negative breast cancer  
Triple-negative breast cancers (TNBCs) represent a heterogeneous subtype of 
breast cancers that are associated with an aggressive clinical conditions and poor 
prognosis, where targeted therapies are currently limited[12].  The majority of TNBCs 
belong to the basal-like category. Their clinical and pathologic features overlap with 
hereditary BRCA1 related breast cancers[13], [14].  TNBCs are characterized by the 
absence of ER, progesterone receptor (PR) and lack of HER2 expression[15]. 
Therefore, TNBCs have more aggressive clinical course than other forms of breast 
cancers, with an increased likelihood of recurrence and death[16]. 
1.3 Molecular mechanisms targeted in cancer  
Several cellular processes and molecular mechanisms are targeted in cancer 
treatment. These mechanisms include DNA damage, cell cycle, senescence and cell 
death.   
1.3.1 DNA damage  
DNA damage is an alteration in DNA which can be caused by different 
stressors. These stressors include radiations such as UV light and X-rays, chemicals 
and reactive oxygen species (ROS)[17]. In response to such stresses, cells activate 
several mechanisms to repair DNA and maintain genomic integrity[18], [19]. If DNA 
damage was beyond the cell’s repair capacity, then cell cycle arrest and/or cell death 
might occur to eliminate potentially dangerous mutations[20].  One example of DNA 
damage is double strand breakages that are detected by γH2AX marker. H2AX histone 
variant becomes rapidly phosphorylated, upon double strand breaks, at serine 139 to 






repair and chromatin remodelling[21],[22]. As the double strand breakages are 
repaired, dephosphorylation of γH2AX occur and the cell goes into its normal 
state[23], [24]. 
1.3.1.1 DNA damage and cancer  
Accumulation of DNA damage that is beyond repair capacity, or defect in DNA 
repair pathways leads to mutations or chromosomal aberrations that affect oncogenes 
and tumor suppressor genes. As a result, cells could undergo malignant transformation 
into cancer[25]. In cancer cells, defects in DNA repair pathways enable cancer cells to 
accumulate genomic alterations that contribute to their aggressive phenotype[26]. 
Alterations in DNA repair pathways can make some cancer cells depend on less DNA 
repair pathways for survival. Moreover, there are specific DNA repair pathways that 
enable cancer cells to survive DNA damage that is induced by chemotherapeutic 
treatments, making them resistant to such drugs[27]. 
1.3.2 Cell cycle 
Cancer is characterized by uncontrolled proliferation and dysregulated cell 
cycle control. Cell proliferation involves the reproduction of a cell to form two 
daughter cells[28]. Cell cycle consists of distinct phases. The major phases are S and 
M phases. In S phase, DNA is replicated and chromosomes are duplicated. While M 
phase consists of two events: nuclear division (mitosis) and cell division (cytokinesis). 
Interphase comprises the end of M phase and the beginning of the next. Most cell 
cycles includes gap phases in between S and M phases. G1 occurs before S phase and 
G2 before M phase. Gap phases provide additional time for cells to grow. It also serve 
as regulatory transitions that controls the progression to the next stage of cell cycle. 






from cell cycle. In the presence of unfavorable growth conditions cells go into 
prolonged G1 or exit into non-dividing state called G0[29]. 
1.3.2.1 Control system 
Cell cycle is controlled by a regulatory network[30]. The changes in gene 
expression as a function of cell cycle progression are regulated by specific cyclin 
dependent kinases (CDKs) activities[31]. CDKs are protein kinase subunits that forms 
complexes with a regulatory cyclin proteins. Cyclins are synthesized and destroyed at 
specific times during cell cycle, thus regulating kinase activity.  Human cells contain 
multiple CDKs and cyclins. However, only certain subset of CDK–cyclin complexes 
are directly involved in driving the cell cycle. They include three interphase CDKs 
(CDK2, CDK4 and CDK6), a mitotic CDK (CDK1, also known as cell division control 
protein 2 (CDC2)) and ten cyclins that belong to four different classes (the A, B, D 
and E cyclins)[32], [33].   
1.3.2.1.1 Checkpoints 
There are two crucial aspects of cell cycle regulation: DNA structure 
checkpoints, which arrest the cell cycle in response to DNA damage or incomplete 
replication, and commitment point in which a cell becomes committed to enter the cell 
cycle and progress through it independently of signals from the environment[34].  
DNA checkpoints sense possible defects during DNA synthesis and chromosome 
segregation. They respond to internal stresses such as incomplete replication or 
external stresses such as DNA damaging agents to block cell cycle progression. Cell 
cycle arrest allows cells to properly repair these defects, thus preventing their 






The major checkpoints are DNA damage checkpoints: at entry into S phase 
(G1–S checkpoint) and mitosis (G2–M checkpoint), and the spindle checkpoint that 
controls progression into anaphase[28]. DNA damage checkpoints protect cells from 
exogenous and endogenous genotoxic agents that induce diverse alterations in the 
DNA molecule. These alterations are sensed by signalling pathways that ultimately 
leads to CDK inhibition and cell cycle arrest[36]. If repair is unsuccessful because of 
the excessive DNA damage or genetic defects in either the checkpoint or the DNA 
repair machinery, cells may enter senescence or undergo apoptosis[37]. Spindle 
assembly checkpoint controls the proper segregation of the chromosomes once the 
genetic material is duplicated. It has a signalling pathway that modulates CDK1 
activity and prevent defects in chromosome segregation[38], [39].  
1.3.2.2 Cell cycle and cancer 
The loss of checkpoint controls in cancer cells make them less sensitive to the 
normal growth signals that regulate normal cell proliferation. Tumor cells accumulate 
mutations that result in constitutive growth signalling and defective responses to anti-
growth signals that contribute to unscheduled proliferation[32], [33], [40]. Most 
tumors acquire genomic instability that leads to additional mutations as well as 
chromosomal instability[37], [38]. These alterations result in proliferative advantages 
and increased susceptibility to the accumulation of additional genetic alterations that 
contribute to tumor progression and acquisition of more aggressive phenotypes. Cell 
cycle defects are mediated, directly or indirectly, by misregulation of CDKs[41].  
1.3.3 Senescence  
Senescence was first described by Hayflick and Moorhead as they showed that 






various stressors by undergoing cellular senescence as shown in Figure 1[43]. Cells 
loose the ability to proliferate while remaining alive.[44]. Senescent cells adopt 
morphological changes that are characterized by flattened shape and enlarged size[43], 
[45]. Senescent cells exhibit specific molecular markers such as senescence-associated 
β-galactosidase (SA-β-gal) and senescence-associated heterochromatin foci 
(SAHF)[46], [47]. SA-β-gal activity is known to be increased in senescent cells. This 
increase is likely due to an increased lysosomal content of senescent cells, giving rise 
to an elevated β-galactosidase activity that becomes detectable at pH 6[45], [48]. 
However, there is no evidence on the actual involvement of this enzyme in senescence 
pathway[49].  
 







1.3.3.1 Senescence and cancer  
Mouse models of cancer have demonstrated that senescence is associated with 
pre-malignant stages of neoplastic transformation and has a crucial function in 
preventing tumor progression. Interestingly, senescent tumor cells are not only growth 
arrested but can be also cleared by phagocytic cells[50].  Loss or inactivation of tumor 
suppressor genes are associated with impaired senescence[51]. Therapeutic 
approaches such as p53-tumor suppressor gene- reactivation, inhibition of c-MYC-
oncogene- in tumors or treatment with cyclin-dependent kinase (CDK) inhibitors have 
proven to be effective by stimulating a senescence response[52]. Therefore, malignant 
tumors, despite their impaired ability to undergo senescence, can still be forced into 
senescence if crucial oncogenic pathways are disabled or tumor suppressors are 
restored. Therefore, senescence-inducing drugs could represent an ideal opportunity 
to increase the arsenal of anticancer weapons[51].  
1.3.4 Programed cell death  
Programmed cell death (PCD) is essential for the development and 
maintenance of multicellular organisms. Two self-destructive processes, autophagy 
(‘self-eating’) and apoptosis (‘self-killing’), have captivated the imagination of 
scientists. Thus, apoptosis and autophagy constitute two processes through which 
damaged or aged cells or organelles are eliminated[53].  
1.3.4.1 Apoptosis (programmed cell death I) 
Apoptosis is a tightly regulated multi-step pathway responsible for cell death 
not only during development, but also in adult multicellular organisms to maintain 
homeostasis. Key characteristics of apoptosis are cellular shrinkage, condensation of 






become rounded and retracted from neighboring cells which is accompanied by plasma 
membrane blebbing[56], [57]. A dominant signal of apoptosis is the translocation of 
phosphatidylserine from the inner to the outer side of the plasma membrane. This ‘eat-
me’ indicator functions as a recognition signal for phagocytic cells to engulf apoptotic 
cells[58]. Apoptosis occur in a controlled manner to minimize damage and disruption 
to neighboring cells[54]. Apoptosis is orchestrated primarily, but not exclusively, by 
members of cysteine proteases family known as caspases[59]. 
1.3.4.1.2 Apoptosis and cancer  
To cope with DNA damage, cells have evolved a sophisticated repair system. 
Failure of this system leads to genomic instability, which triggers apoptosis under 
normal physiological circumstances. Mutations in key apoptosis signalling proteins 
and oncogene activation result in evading apoptosis, which ultimately lead to tumor 
development[58]. 
1.3.4.2 Autophagy (programmed cell death II)  
Autophagy is a highly regulated process that can either be involved in the 
turnover of long-lived proteins and whole organelles or can specifically target distinct 
organelles (for example, mitochondria in mitophagy and the endoplasmic reticulum 
(ER) in reticulophagy), thereby eliminating supernumerary or damaged 
organelles[60].  
Autophagy can act as cellular survival mechanism or cell death. Autophagy can 
protect cells against death, as a cytoprotection mechanisms, autophagy mediates the 
removal of protein aggregates that otherwise will lead to cellular dysfunction. On the 
other hand, autophagy can mediate cellular death. One way by killing, where 






irreversible cellular atrophy with a consequent collapse of vital cellular functions. 
Indeed, during extensive autophagy, the volume that is occupied by autophagic 
vacuoles and dense bodies may be roughly equal to, or greater than, that of ‘free’ 
cytosol and organelles. Autophagy can also mediate cellular death by triggering 
apoptosis or necrosis as a primary response to stress stimuli[61], [62]. 
1.3.4.2.1 Mechanism of autophagy  
Autophagy starts with the engulfment of cytoplasmic material by the 
phagophore inside an intact cell, which sequesters material in double-membraned 
vesicles named autophagosomes.  
Among the initial steps of vesicle nucleation is the activation of Vps34, a class 
III phosphatidylinositol 3‑kinase (PI3K), to generate phosphatidylinositol-3-
phosphate (PtdIns3P). Vps34 activation depends on the formation of a multiprotein 
complex in which beclin-1 is involved. This complex recruits autophagy related genes 
(Atg) that are essential for autophagosome formation. Atg 5, 7 and 8 complex 
promotes the recruitment and conversion of the cytosolic microtubule-associated 
protein light chain 3-I (LC3-I) into LC3-II by cysteine protease Atg4. LC3-II will be 
incorporated into the autophagosome membrane[53], [63]. A simplified scheme of 
autophagy mechanism is illustrated in Figure 2[64].  LC3-II also binds to the adaptor 
protein p62/sequestosome1 (SQSTM 1), which is involved in trafficking proteins to 
the proteasome and serves to facilitate the autophagic degradation of ubiquitinated 
protein aggregates[65]. p62/SQSTM 1 is normally degraded during autophagy and 
accumulates when autophagy is impaired, as has been shown in autophagy-deficient 
mice[66]. Autophagosomes undergo maturation by fusion with lysosomes to form 






content of the autophagic vacuoles is degraded by lysosomal enzymes that act 
optimally within this acidic compartment[67]. 
 
 
Figure 2: Simplified mechanism of autophagy[64].  
 
1.3.4.2.2 Autophagy and cancer  
The role of autophagy in cancer is multifactorial and highly context-dependent. 
Autophagy is recognized as a survival factor for tumor cells under certain metabolic 
and therapeutic stresses[63]. However, genetic evidence suggested that autophagy 
plays a role in tumor suppression[68]. It was proposed that autophagy functions as a 
tumor suppressor at early stages of tumor development, since the expression of beclin-
1, was found to reduce tumorigenesis through induction of autophagy. Conversely, 
autophagy was found to promote tumor progression at later stages of tumor to survive 
low-oxygen and low-nutrient conditions. Moreover, it was established that autophagy 
protects some cancer cells against anti-cancer drugs by blocking the apoptotic 







1.4 Conventional therapy 
Different types of cancer therapy are used for cancer treatment depending on 
cancer type and stage. These treatments include the following: surgery, radiotherapy, 
chemotherapy.,etc. Surgery aims to remove localized primary tumors. In radiotherapy, 
ionizing radiation are used to target tumor cells where they react with water to generate 
reactive oxygen spices (ROS) that damage the DNA[3]. Chemotherapy aims to target 
highly proliferative cancerous cells.  
1.5 Alternative therapy  
Therapies used nowadays to treat breast cancer has definitely improved 
patients’ disease status. However, the side effects that are accompanied with such 
treatments, sometimes lead to death, beside, aggressive metastasized cancer remains 
untreatable. Therefore, novel therapeutic options are needed to target aggressive type 
of breast cancer with less side effects.  
1.5.1 Plants 
Plants have been used as medicine for many diseases throughout the years. 
They were shown to be a source of new drugs, including anticancer drugs. There are 
compelling evidences from epidemiological and experimental studies that highlight 
the importance of compounds derived from plants “phytochemicals” to reduce the risk 
of several cancers and inhibit the development of tumors in experimental animals. 
With advanced knowledge of molecular science and improvement in isolation and 
purification techniques, many anticancer agents derived from medicinal plants have 






are directly derived from plants, while another 25% are chemically altered natural 
products[70].   
Anticancer drugs derived from plants includes taxol isolated from the bark of 
Taxus brevifolia Nutt, vinblastine and vincristine isolated from Catharanthus roseus, 
camptothecin derivatives isolated from the Chinese Camptotheca acuminata Decne, 
and etoposide derived from epipodophyllotoxin are in clinical use. Several other types 
of promising bioactive compounds of plant origin are currently in clinical trials or 
preclinical trials or undergoing further investigation[71]. 
Moreover, recent studies have tested the crude extract of herbal plants to test 
their anti-cancer effects. For example Origanum majorana extract was found to inhibit 
the viability of triple negative MDA-MB-231 breast cancer cells confirmed by colony 
growth inhibition, and induced cell cycle arrest in M phase at lower concentration. At 
higher concentration, apoptosis was induced through the extrinsic apoptotic pathway. 
Moreover, Origanum majorana extract was found to induce DNA damage[72]. 
In addition to that, several other studies revealed the use of herbal crude 
extracts to have anti-breast cancer activities. For instance,  the aqueous extract of 
Fagonia cretica, used widely as herbal tea, induced cell cycle arrest and apoptosis in 
MCF-7 and MDA-MB-231 breast cancer cell lines, with activation of DNA damage 
response[73]. Huanglian extract (Coptidis rhizoma), a widely used herb in Chinese 
medicine, inhibited cellular growth and apoptosis by upregulation of interferon-β and 
TNF-α in MCF-7 breast cancer cells [74]. Dillenia suffruticosa (Griff) ethyl acetate 
extract caused cytotoxicity to MCF-7 cells and induced apoptosis by modulating 
several genes which are involved in oxidative stress pathway[75]. An ideal 
phytochemical is one that possesses anti-tumor properties with minimal or no toxicity 






1.5.1.1 Rhus coriaria Linn 
Rhus coriaria Linn, commonly known as sumac, belongs to Anacardiacea 
family. R. coriaria is widely distributed in temperate and subtropical regions[77]. It is 
considered to be a flowering shrub where the fruit forms clusters of reddish drupes[78]. 
R. coriaria is known to have therapeutic values and dietary qualities; it is used as a 
medicinal herb, spice and sour drink[79].  
1.5.1.1.1 Rhus coriaria phytochemicals  
According to Abu-Reidah et.al, (2014), 211 phytochemical compounds have 
been characterized using HPLC–DAD–ESI-MS/MS method. These phytochemicals 
are organic acids, phenolic acids, phenolic compounds conjugated with malic acid 
derivatives, flavonoid, isoflavonoid, hydrolysable tannins, anthocyanins, terpenoid 
and other compounds (such as butein, iridoid and coumarin derivatives) [80]. 
1.5.1.1.2 Rhus coriaria mechanism of action  
R. coriaria is considered to be a natural antioxidant; it has the capacity to 
protect cells and organisms against damage caused by oxidative stress. Previous 
studies indicated that antioxidant activities of R. coriaria extract was due to the 
presence of phenolic compounds[77], [81]. Several studies linked the accumulation of 
ROS in the body to different diseases such as atherosclerosis[82], insulin resistance, 
type II diabetes[83], cardiovascular diseases[84], osteoarthritis[85], hepatocytes 
toxicity[86] and DNA damage[87]. Interestingly, R. coriaria extract was found to have 
an effect in all the above mentioned diseases. Moreover, it was shown that R. coriaria 
extract induced hypoglycemic activity in type II diabetic rats; as it reduced the 
postprandial blood glucose (PBG)[88].  In addition, it has antimicrobial activity 






bacteria[89]. A recent study illustrated the cytotoxic and antiangiogenic effects of R. 
coriaria methanolic extract on Y79 retinoblastoma cell line[90]. 
The aim of this study is to investigate the anti-breast cancer effect of R. 








Chapter 2: Materials and Methods 
 
2.1 Cell culture, chemicals and antibodies 
Human breast cancer cells MDA-MB-231 and MCF-7 were maintained in 
DMEM (Hyclone, Cramlington, UK) and T47D in RPMI (Hyclone, Cramlington, 
UK). All media were complemented with 10% fetal bovine serum (FBS) (Hyclone, 
Cramlington, UK) and 100 U/ml penicillin/streptomycin (Hyclone, Cramlington, 
UK). 3-methyadenine (3-MA) and chloroquine (CQ) were purchased from Millipore 
Analyzer (Millipore, Hayward, CA, USA) and Sigma-Aldrich (Saint-Quentin 
FAllavier, France), respectively. Antibodies to p62/SQSTMI and cleaved PARP 
were obtained from Abcam (Abcam, Cambridge, UK). Antibodies to LC3 was 
obtained from Cell Signaling (USA). Antibodies to γH2AX and Beclin-1 were 
obtained from Millipore (Millipore, Hayward, CA, USA). Antibody to β-actin were 
obtained from Santa Cruz Biotechnology, Inc (USA). 
2.2 Preparation of the Rhus coriaria ethanolic extract (RCE) 
Fruits of Rhus coriaria L. were collected from a private farm located at 33° 
16′ 35.59′′ N and 35° 19′ 02.89′′ E. The farm is located in Ma’rakeh, Tyre, Lebanon 
and the approval of the owner was obtained before collecting the fruit or 
commencing any experiments. This plant is neither endangered nor protected by any 
laws and it is readily and commercially available in the market. RCE was prepared 
as previously described[72]. Briefly 10.0 g of the dried fruit were ground to a fine 
powder using a porcelain mortar and pestle. The powder was then suspended in 
100 mL of 70% absolute ethanol and the mixture was kept in the dark for 72 hours 






a glass sintered funnel and the filtrate was evaporated to dryness using a rota-vapor 
at room temperature. The red residue was kept under vacuum for 2–3 hours and its 
mass was recorded. The residue was stored at −20 °C until further use. 
2.3 Measurement of cellular viability 
Cells were seeded in triplicate in 96-well plates at a density of 5,000 
cells/well. After 24 h of culture, cells were treated with or without various 
concentrations of Rhus coriaria extract for different durations. Cell viability was 
measured with the Cell Cytotoxicity Assay Kit (Abcam) according to the 
manufacturer’s specifications. The results are representative of an average of 5 
independent experiments. Data were presented as proportional viability (%) by 
comparing the treated group with the untreated cells, the viability of which is 
assumed to be 100%. 
Cell viability was also measured using the Muse™ Cell Analyzer (Millipore, 
Hayward, CA, USA) using the Muse Count and Viability Kit (Millipore, Hayward, 
CA, USA) which differentially stains viable and dead cells based on their 
permeability to two DNA binding dyes. Briefly, cells were plated onto 12-well 
plates (50 × 104 cells/well) and allowed to grow for 24 h. The day of treatment cells 
were counted to estimate the approximate number of cells per well. Following RCE 
treatment at indicated times, viable cells were counted using Muse™ Cell Analyzer.  
2.4 Cell cycle analysis 
The cell cycle distribution analysis in control and RCE-treated MDA-MB-






USA) using the Muse™ Cell Cycle Kit (Millipore, Hayward, CA, USA) according 
to the manufacturer’s instructions. Briefly, cells grown onto 6 cm culture dishes 
were treated with or without various concentrations of RCE. After 24 h or 48 h of 
treatment, cells were collected by trypsinization, washed in PBS and resuspended 
in complete media and the Muse cell cycle test reagent was then added to each test 
tube. Cells were then incubated for 30 min at room temperature in the dark. After 
staining, the cells were processed for cell cycle analysis. Percentage of cells in 
G0/G1, S and G2/M phases were determined using the FlowJo software.  
2.5 Quantification of apoptosis by Annexin V labelling 
Apoptosis was examined using the Annexin V & Dead Cell kit (Millipore, 
Hayward, CA, USA) according to the manufacturer’s instructions. Briefly, MDA-
MB-231 cells were treated with or without RCE for 48 h. Detached and adherent 
cells were collected and incubated with Annexin V and 7-AAD, a dead cell marker, 
for 20 min at room temperature in the dark. The events for live, early and late 
apoptotic cells were counted with the Muse™ Cell Analyzer (Millipore, Hayward, 
CA, USA). 
2.6 Hematoxylin-eosin staining of cells 
MDA-MB 231 cells (5 × 104) were grown on 2 well labtek chamber slide for 
24 h, then treated with and without RCE for 48 h. Cells were then washed twice with 
PBS and fixed in 10% formalin solution (4% paraformaldehyde) for 5 min at room 
temperature followed by permeabilization in 70% ethanol. Cells were then washed 
three times with PBS, stained with hematoxylin for 1 min and washed again before 






50% glycerol, sealed and observed under Olympus microscope (BX41) fitted with 
Olympus camera (DP71). 
2.7 Senescence-Associated-β-Galactosidase (SA-β-gal) staining 
Briefly 105 MDA-MB-231 cells were cultured in 6 well plate and treated 
with and without RCE for 48 h. Treated and control cells were then washed in PBS, 
and fixed with 2% formaldehyde/0.2% glutaraldehyde for 5 min at room 
temperature. The SA-β-gal staining was performed as previously described. 
2.8 Whole cell extract and western blotting analysis 
Cells (1.8 × 106) were seeded in 10 cm culture dishes and cultured for 24 h 
before addition of RCE. After incubation, cells were washed twice with ice-cold 
PBS, scraped, pelleted and lysed in RIPA buffer (Pierce) supplemented with 
protease inhibitor cocktail (Roche) and phosphatase inhibitor (Roche). After 
incubation for 30 min on ice, cell lysates were centrifuged at 14,000 rpm for 20 min 
at 4 °C. Protein concentration of lysates was determined by BCA protein assay kit 
(Thermo Scientific) and the lysates were adjusted with lysis buffer. Aliquots of 
25 μg of total cell lysate were resolved onto 8–15% SDS-PAGE. Proteins were 
transferred to nitrocellulose membranes (Thermo Scientific) and blocked for 1 h at 
room temperature with 5% non-fat dry milk in TBST (Tris-buffered saline with 
0.05% Tween 20). Incubation with specific primary antibodies was performed in 
blocking buffer overnight at 4 °C. Horseradish peroxidase-conjugated anti-IgG was 
used as secondary antibody. Immunoreactive bands were detected by ECL 






stripped in Restore western blot stripping buffer (Thermo Scientific) according to 
the manufacturer’s instructions. 
2.9 Statistical analysis 
The statistical analysis were done using SPSS version 21. Data were reported 
as group mean ± SEM. The data were analyzed via t-test, univariate test and one-
way ANOVA followed by LSD’s Post-Hoc multiple comparison test (to compare 
all groups). Significance for all statistical comparisons was set at p < 0.05 using a 






Chapter 3: Results 
3.1 The inhibitory effect of Rhus coriaria extract on MDA-MB-231, MCF-7 and 
T47D breast cancer cell lines 
We wanted first to test the anti-cancer activity of Rhus coriaria extract 
(RCE) on breast cancer cells. Toward this, we measured the effect of different 
concentrations of the RCE (0, 50, 100, 200, 400 and 600 μg/mL) on the proliferation 
of three different breast cancer cell lines (MDA-MB-231, MCF-7 and T47D). Our 
results indicate that RCE decreased cellular viability in concentration and time-
dependent manners (Fig. 3A–C).  
  By determining the IC50 –which is the concentration at which the drug cause 
50% inhibition - for each cell line, it appears that T47D and MDA-MB-231 exhibit 
a greater sensitivity to RCE compared to the MCF-7 cells (Table 1). Then we 
focused on MDA-MB-231 cells since it belongs to the highly aggressive triple 
negative breast cancer for further investigation.  
 
IC50 (µg/mL) 
 24 h 48 h 72h 
MDA-MB-231 437 305 283 
T47D 374 261 229 
MCF-7 ND 510 433 
 




























Figure 3: Rhus coriaria extract (RCE) inhibited cellular viability of (A)MDA-MB-
231, (B) T47-D and (C) MCF-7 breast cancer cell lines treated with or without the 
indicated concentrations of RCE for 24h, 48h and 72h.  Data represent the mean of 
five independent experiments carried out in triplicate. Statistical analysis for cell 
viability data was performed using one-way ANOVA followed by LSD Post-Hoc test 







3.2 Inhibition of proliferation recovery after removal of Rhus coriaria extract 
Next, we examined whether or not, RCE can suppress the potential of breast 
cancer cells to recover proliferative capability. Cells were first treated with the 
indicated concentration of RCE for 24 h, and then washed with PBS and placed in 
fresh complete media in the absence of RCE, and allowed to grow for another 48 h 
before assessing cell viability by cell counting. Figure 4, indicates that MDA-MB-
231 cells failed to recover proliferative capability as the number of viable cells kept 
reducing even after RCE removal. Thus, our result indicates that RCE exerts an 
irreversible anti-proliferative effect on breast cancer cells. 
 
Figure 4: Inhibition of cellular viability recovery after RCE removal. MDA-MB-231 
cells were exposed to RCE for 24 h, then, cells were washed and allowed to grow for 
another 48 h in fresh complete media. Cell viability was monitored using the Muse 






3.3 Induction of G1 arrest in Rhus coriaria treated cells 
To investigate the mechanism(s) underlying the inhibitory activity of RCE 
on breast cancer cells, we examined its effect on cell cycle progression. MDA-MB-
231 cells were treated with indicated concentrations of RCE for 24 h and 48 h and 
were subjected to cell cycle analysis. Treating cells with RCE caused a significant 
inhibition of cell cycle progression in MDA-MB-231 cells at 24 and 48 h leading to 
an increase in the G1 population.  
 
Figure 5: Induction of cell cycle arrest at G1 in MDA-MB-231 cells. Cell cycle 
distribution analysis of RCE-induced G1 cell-cycle block. MDA-MB 231 cells were 
first treated with RCE at the indicated concentrations for 24 h and 48 h, and then 







3.4 Induction of senescence in Rhus coriaria treated cells 
The induction of cell cycle arrest at G1 phase prompted us to examine if the 
arrested cells did indeed undergo senescence. Our results show that senescence was 
detected after treating the cells for 48 h.  Almost 21% of the cells that expressed 
SA-β-galctosidase were detected at 200 μg/mL of RCE. After 96 h of treatment 
senescent cells nearly doubled at the same concentration. Taken together, these data 
suggest that induction of senescence might contribute to the inhibitory effect of RCE 
on the proliferation of MDA-MB-231 cells (fig. 6). 
 
Figure 6: Induction of senescence in MDA-MB-231 cells. MDA-MB 231 cells were 
incubated with RCE (200 μg/mL) for 48 and 96 hours and stained for SA-β-
Galactosidase activity to detect senescence. Data are representative of three 
independent experiments. Statistical analysis was performed using one-way ANOVA 






3.5 Minimal induction of apoptosis in MDA-MB-231 treated with Rhus coriaria 
extract 
Since RCE decreased cellular viability in MDA-MB-231 cell, we decided to 
investigate the mechanism by which RCE decreased cellular viability. First we 
checked whether or not the decreased viability is associated with apoptosis. 
Therefore, we stained for Annexin V to determine the percentage of apoptotic cells 
induced by RCE after 48 h treatment. Exposure to RCE did not lead to a significant 
change in the early stage apoptotic population (Annexin V+/7-AAD−). An increase 
but still minimal in the late stage apoptotic/necrotic cells (Annexin V+/PI+) (fig.7 
AB) was observed at highest RCE concentration, suggesting minimal apoptotic cell 
death induced by RCE in MDA-MB-231 cells. Apoptosis was further assessed by 
Poly (ADP-ribose) polymerase (PARP) cleavage.  PARP is a nuclear enzyme 
involved in DNA repair, and it is a well-known substrate for caspase-3 cleavage 
during apoptosis[91]. Cells treated with etoposide (50 μM) for 24 h, a condition that 
was reported to induce apoptosis, was used as positive control. Despite the high 
level of concentration- and time-dependent cell death observed by cell toxicity and 
cell counting assay during the first 72 h of RCE treatment, very little PARP 
cleavage, was observed in RCE-treated MDA-MB-231 cells (fig. 7C). Altogether, 
Annexin V staining and PARP cleavage data support the conclusion of minimal 







Figure 7: Minimal induction of apoptosis in the MDA-MB-231 cells. (A-B) Annexin 
V binding was carried out using Annexin V & Dead Cell kit (Millipore). Cells were 
treated with or without increasing concentrations of RCE for 48 h. Detached and 
adherent cells were collected and stained with Annexin V and 7-AAD and then the 
events for early and late apoptotic cells were counted by Muse Cell Analyzer. Data 
represent the mean ± SEM of at least 3 independent experiments. Statistical analysis 
was performed using ANOVA followed by LSD Post-Hoc test to determine the 
significance (*p < 0.05, **p < 0.005, ***p < 0.001).  (C) Western blot analysis of 
PARP cleavage in MDA-MB-231. Cells were treated with increasing concentrations 
of RCE (200, 400 and 600 μg/mL) for 48 h and 72 h. Exposure of cell to etoposide 
(50 μM) for 24 h was used as a positive control for apoptosis.  
 
3.6 Induction of autophagy in MDA-MB-231 treated with Rhus coriaria extract  
Eosin/hematoxylin staining of MDA-MB-231 cells treated with RCE 
revealed massive cytoplasmic vacuolation that might indicate induction of 
autophagy (Fig. 8A). In order to determine whether indeed this vacuolation resulted 
from activation of autophagy. And to further confirm autophagy induction in RCE-






in MDA-MB-231 treated with various concentrations of RCE. RCE induced a 
concentration-dependent accumulation of the LC3-II (fig. 8B). The expression of 
p62 (SQSTM1) was also evaluated. There was a concentration-dependent decrease 
in p62 (SQSTM1) (fig. 8B). Hence, the conversion of LC3I/II along with the 
downregulation of p62 (SQSTM1) confirm the formation of autophagosome in 
RCE-treated MDA-MB-231 cells. Next we assessed the expression of beclin-1. 
Western blotting data showed that the level of Beclin-1 also increased in 
concentration-dependent manner. Taken together, Western blotting results along 
with eosin/hematoxylin staining, confirms the activation of autophagy in breast 
cancer cells in response to RCE treatment.  
  
 
Figure 8: Induction of autophagy in RCE treated MDA-MB-231 cells. (A) MDA-MB-
231 cells were treated for 48 h with RCE (400 µg/mL) and then stained with eosin-
hematoxylin. (B) Cells were treated with or without increasing concentration of RCE for 48 h, 
then whole cell proteins were extracted and subjected to Western blot analysis for LC3II, 







3.7 Autophagy blockage reduces cell death and senescence in Rhus coriaria-
treated cells 
The observation that RCE induces robust cell death in MDA-MB-231 cells and, that 
induction of apoptosis is minimal raised the question of whether autophagy is 
responsible for the cytotoxicity activity of RCE through activation of type II 
programmed cell death and therefore its blockade by autophagy inhibitors might 
render cells less susceptible to RCE treatment. We used two widely used autophagy 
inhibitors, 3-methyladenine (3-MA), phosphatidylinositol 3-phosphate kinase 
(PI3K) inhibitor, which blocks autophagosome formation[69] and chloroquine 
(CQ), inhibitor of lysosomal acidification, which blocks the fusion between 
autophagosomes and lysosomes[53]. Results showed that autophagy was markedly 
inhibited by 3-MA, evident by decreased conversion of LC3-I to LC3-II (fig.9A). 
However, when cells were pre-treated with CQ, LC3-II protein accumulated to some 
extent (fig.9A). Next we tested the effect of these inhibitors on the cellular viability 
of MDA-MB-231 cells treated with RCE.  We found that cell viability was markedly 
improved in the presence of 3-MA or CQ when compared with RCE alone, 
suggesting that RCE-induced cell death is significantly dependent on autophagy 
induction (fig. 9B). Furthermore, inhibition of autophagy neither increased nor 
reduced the level of cleaved PARP, suggesting that RCE-mediated apoptosis and 
autophagy in MDA-MB-231 might occur independently from each other (fig. 9B).  
Because blockade of autophagy improved cell viability, and because SA-β-
galactosidase was also detected in autophagic cells, we asked the question whether 
blocking autophagy can also affect senescence in RCE-treated cells. Figure 
9D shows that the number of senescent cells in wells containing both CQ and RCE 






that autophagy and senescence are linked events and that induction of senescence is 
at least partly dependent upon the activation of autophagy. 
 
 
Figure 9: Effects of autophagy inhibitors on cell death, apoptosis and senescence. (A) 
Analysis of LC3-II accumulation in MDA-MB-231 cells. Cells were pre-treated with 
or without 3-MA (5 mM) or CQ (50 μM) for 1 h and then RCE was added at the 
indicated concentrations for 48 h. Proteins were extracted and LC3-II accumulation 
was determined by western blot. (B) Inhibition of autophagy reduces cell death 
induced by RCE. MDA-MB-231 cells were pre-treated as described above and treated 
for 48 h with 400 or 600 μg/mL RCE. Data are representative of three independent 
experiments. Statistical analysis of cell viability on control or treated cells was 
performed using one-way ANOVA followed by LSD Post-Hoc test to determine 
significance (*p < 0.05, **p < 0.005, ***p < 0.001). (C) Western blot of cleaved 
PARP in cells pre-treated with and without autophagy inhibitors. (D) Effect of 
autophagy blockade on RCE-induced senescence. Cells were treated as described in A 
and stained for SA-β-Gal activity to detect senescence. Data are representative of three 
independent experiments. Statistical analysis of senescent cells count on control or 








3.8 Rhus coriaria induces DNA damage as an early event that precedes autophagy 
Next, we sought to investigate whether RCE induces DNA damage in MDA-
MB-231 cells. Western blotting analysis revealed a concentration-dependent 
increase in the levels of phosphorylated H2AX (γH2AX) (fig. 10A), indicating an 
accumulation of double strand breaks in treated cells. In order to assess whether 
DNA damage is an early event, a time-course measurement of γH2AX in cells 
treated with 400 μg/mL RCE was carried out. We found that activation of γH2AX 
occurred as early as 6 h post-treatment (fig. 10B). To further test whether DNA 
damage precedes autophagy, MDA-MB-231 cells were first incubated for 1 h with 
the autophagy inhibitor CQ and then treated with the indicated concentration of 
RCE. Figure 10C, shows that inhibition of autophagy did not prevent DNA damage 
in treated cells. Taken together, these results indicate that DNA damage is an earlier 
event in RCE-treated cells. This damage might then serve as a trigger for 
downstream responses. Based on these findings, we hypothesize that DNA damage 









Figure 10: Accumulation of DNA damage in RCE treated MDA-MB-231. (A) 
Concentration-dependent accumulation of γH2AX, in RCE-treated cells. MDA-MB-
231 cells were treated with and without increasing concentrations of RCE for 48 h and 
DNA damage was analyzed, by determining the level of γH2AX accumulation using 
anti- phospho-H2AX (ser 139) antibody. (B) Time-course measurement of DNA 
damage in treated MDA-MB-231 cells. Cells were treated with 400 μg/mL RCE and 
DNA damage was examined, at different time-point (6, 12, 24 and 48 h). (C) Effect of 
autophagy inhibitor on the accumulation of DNA damage. Cells were pre-treated with 
CQ (50 μM) for 1 h before adding RCE (400 and 600 μg/mL) for 48 h. Cells were then 







Chapter 4: Discussion 
 
Accumulating evidences demonstrated that several natural compounds derived 
from plants were found to play a positive role in cancer prevention and treatment 
through modulating autophagy, which became a promising target for developing 
potential therapeutic drugs[92]. In our study we investigated the anticancer activity of 
Rhus coriaria on human breast cancer cells. Our work demonstrated that Rhus coriaria 
ethanolic extract (RCE) decreased the cellular viability of three breast cancer cell lines 
(MDA-MB-231, T47D and MCF-7) in a time- and a concentration-dependent manner. 
Moreover, it induced an irreversible effect on the survival of the MDA-MB-231 cell 
line after the removal of RCE since cells were unable to recover their proliferation. 
RCE induced irreversible cell cycle arrest at G1 phase and senescence detected by the 
elevated expression of SA-β-Gal. Furthermore, we found that RCE induced autophagy 
which was the main mechanism of cell death. Induction of DNA damage was also 
detected by increased expression of γH2AX.  
Inhibition of cellular viability by RCE was observed on three breast cancer cell 
lines although they obtain different characteristics. MDA-MB-231 cell line is 
originated from adenocarcinoma and the state of its estrogen and progesterone 
receptors are negative and its p53 gene is mutated. T47D is derived from ductal 
carcinoma and the state of its estrogen and progesterone receptors are positive and its 
p53 gene is mutated as well.   MCF-7 is originated from adenocarcinoma and the state 
of its estrogen receptor is positive while the progesterone receptor is negative and its 
p53 gene is wild type[93]. However we focused on MDA-MB-231 cell line since it 
belongs to the TNBCs which are characterized by being a highly aggressive form of 






Treatment with chemotherapy is not always toxic to all cancer cells; some of 
the cells survive the treatment, recover and resume their proliferation[95]. Therefore, 
it is challenging to find drugs that induce irreversible inhibition to uncontrolled cellular 
growth. Interestingly, our work demonstrated that RCE was able to suppress the 
capability of MDA-MB-231 cells to recover its proliferative potential at concentrations 
of 400 and 600 µg/mL, which were the concentrations at which cell death was detected.   
It has been proposed that cellular senescence refers to permanent cell cycle 
arrest in G1 phase in response to different stressors[43] as cells lose the ability to 
proliferate[44].  In line with the previously published results, our results showed that 
RCE induced cell cycle arrest at G1 phase and cellular senescence marked by increased 
expression of SA-β-Gal activity after 48 h of treatment.  
Some tumors  were found to undergo both autophagic cell death and  apoptosis 
in response to cancer therapy[69]. Apoptosis and autophagy are not always separate 
events, there might be a crosstalk between them[53]. Here, we showed that RCE 
prompted minimal apoptosis while the main cellular death mechanism was autophagy. 
However, the conditions under which autophagy can function as a primary cell death 
mechanism remain to be defined. As discussed earlier, p62/SQSTM 1 is normally 
degraded during autophagy and accumulates when autophagy is impaired, as has been 
shown in autophagy-deficient mice[66]. This, in agreement with our results, which 
illustrated that P62/SQSTM1 was decreased with increasing concentrations of RCE.  
Several studies revealed that when autophagy is inhibited, apoptosis is promoted in 
cancer cells[53]. Unlike these studies, our data showed that when autophagy was 
inhibited by CQ, there was no induction of apoptosis, suggesting that these two 






In cellular context, autophagy has dual function in cellular survival and death. 
Autophagy promote cellular survival as a protective mechanism due to cellular 
stressors, however extensive autophagy can lead to cell death[96]. Recently, DNA 
damage has been shown to induce autophagy, but the exact mechanisms by which 
DNA damage triggers autophagy are still unclear[97]. As we observed in our results, 
γH2AX was induced in a dose-dependent manner upon treating the cells with RCE and 
the inhibition of autophagy did not cause any change in γH2AX expression suggesting 
that DNA damage is a prerequisite for autophagy. In addition to that DNA damage 
was also shown to cause cells to undergo senescence[98]. Moreover, it was shown that 
stress-induced senescence occur in tumor cells in vitro and in vivo through the 
exposure of cells to cytotoxic agents that are found to cause DNA damage[44]. Here 
we demonstrated that cellular senescence was detected after 48 h while DNA damage 
was detected as early as 6 h suggesting that DNA damage is an early step that precedes 
cellular senescence. We propose that this damage might serve as a trigger for 
downstream responses leading to autophagy, senescence and cell death.  
It has been shown that increased autophagic activity was associated with 
senescence in different models, suggesting that autophagy might be an integrated part 
of senescence program[99]. A positive correlation between autophagy and senescence 
was also observed where the inhibition of autophagy decreased the number of 
senescent cells[100]. Moreover, it was shown that inhibition of autophagy by 3-MA 
decreased the number of SA-β-Gal- positive cells[101]. Here, we showed that low 
concentration of RCE (200 µg/mL) caused autophagy in association with cellular 




















Figure 11: Hypothetical model demonstrating the differential effect of Rhus coriaria 
Extract. 
 
 In summary, our data are consistent with a model shown in Figure 11, in which 
treatment with RCE induce autophagy in MDA-MB-231 TNBC cell line.  The 
magnitude of damage, which depends upon the concentration of RCE, determines the 
response of the cells. We propose that at lower concentration of RCE (100 and 200 
µg/mL) there was a limited induction of γH2AX, where cells respond by triggering 
autophagy as a survival mechanism followed by cellular senescence. On the other 
hand, higher concentrations of RCE (400 and 600 µg/mL) caused excessive amounts 
of DNA damage that was beyond the capacity of the cell to repair, thus results in 






Chapter 5: Conclusion 
 
In conclusion, our study demonstrated, for the first time, the potential role of 
Rhus coriaria, as an anti-breast cancer agent in vitro. This study provides preliminary 
data that proposes Rhus coriaria as a valuable source of potentially new natural anti-
breast cancer compound(s) that act by triggering senescence and autophagic cell death. 
Further exploration of this plant is urged in order to identify the bioactive 
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